Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
193
Recruiting, industry sponsors, Cardiovascular and metabolic, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting193
- Completed2,436
193 trials
Showing 1 to 25, recently updated first.
- A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight (VESPER-SUI)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07932925 · 900 participants (planned) · Start Nov 17, 2026 · Primary completion Oct 13, 2028
Drug: Berobenatide; Placebo · For: Urinary Incontinence, Stress; Overweight and/or Obesity
Sites: Citrus Heights, California; Sacramento, California; Boynton Beach, Florida · 11 sites in all
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPivotal-lookingRecruiting
CytokineticsIndustry
NCT06736574 · 1,800 participants (planned) · Start Dec 19, 2024 · Primary completion Sep 2027
Drug: Omecamtiv Mecarbil (OM); Placebo · For: Heart Failure; Heart Failure With Reduced Ejection Fraction
Sites: Alexander City, Alabama; Birmingham, Alabama; Tucson, Arizona · 215 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881458 · 1,000 participants (planned) · Start Oct 16, 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Tirzepatide · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Tucson, Arizona; Escondido, California; Los Alamitos, California · 96 sites in all
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07854782 · 1,500 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 3, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD
Sites: Miami, Florida; Marrero, Louisiana; Metairie, Louisiana · 5 sites in all
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07052903 · 2,250 participants (planned) · Start Jul 2, 2025 · Primary completion May 28, 2030
Drug: Nucresiran; Sterile Normal Saline (0.9% NaCl) · For: Transthyretin Amyloidosis With Cardiomyopathy
Sites: La Jolla, California; Laguna Hills, California; Stanford, California · 267 sites in all
- Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07575399 · 300 participants (planned) · Start May 11, 2026 · Primary completion Jan 3, 2028
Drug: Maridebart Cafraglutide · For: Obesity or Overweight
Sites: Pelham, Alabama; Chandler, Arizona; Sun City, Arizona · 59 sites in all
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07474649 · 103 participants (planned) · Start Sep 14, 2026 · Primary completion Jun 1, 2028
Drug: Bempedoic acid; Ezetimibe and 2 more · For: Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia
Sites: Berlin, Germany; Hamburg, Germany; Mainz, Germany · 12 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07430956 · 2,628 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 28, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Glendale, Arizona; Little Rock, Arkansas · 45 sites in all
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868939 · 560 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: VK2735 Oral; Placebo Comparator · For: Weight Loss
Sites: Tucson, Arizona; Lake Forest, California; Ocoee, Florida · 19 sites in all
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868835 · 560 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: VK2735; Placebo comparator · For: Weight Loss
Sites: Tucson, Arizona; Chula Vista, California; Lake Forest, California · 20 sites in all
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07754461 · 600 participants (planned) · Start Aug 24, 2026 · Primary completion Jan 17, 2028
Drug: Placebo; Survodutide · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Gilbert, Arizona; Paradise Valley, Arizona · 121 sites in all
- Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic StrokePivotal-lookingRecruiting
Pharmazz, Inc.Industry
NCT05691244 · 514 participants (planned) · Start Jul 24, 2025 · Primary completion Sep 2027
Drug: Drug: Normal Saline; Sovateltide · For: Acute Ischemic Stroke; Cerebral Stroke
Sites: Tucson, Arizona; Carmichael, California; Oxnard, California · 57 sites in all
- A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07088068 · 723 participants (planned) · Start Aug 6, 2025 · Primary completion Jun 6, 2028
Drug: Teplizumab · For: Type 1 Diabetes Mellitus
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 201 sites in all
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05714085 · 342 participants (planned) · Start May 31, 2023 · Primary completion Aug 20, 2029
Drug: Vericiguat tablet; Vericiguat suspension and 2 more · For: Heart Failure; Left Ventricular Systolic Dysfunction
Sites: Los Angeles, California; Palo Alto, California; San Bernardino, California · 112 sites in all
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06424288 · 6,712 participants (planned) · Start Jun 17, 2024 · Primary completion May 22, 2028
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Mobile, Alabama; Chula Vista, California; Orange, California · 672 sites in all
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705555 · 960 participants (planned) · Start Aug 27, 2026 · Primary completion Oct 31, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Gilbert, Arizona; Glendale, California; Sacramento, California · 45 sites in all
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06935370 · 4,200 participants (planned) · Start May 20, 2025 · Primary completion Feb 4, 2029
Drug: vicadrostat; empagliflozin and 1 more · For: Heart Failure
Sites: Beverly Hills, California; Covina, California; Encinitas, California · 596 sites in all
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyPivotal-lookingRecruiting
Gan & Lee Pharmaceuticals.Industry
NCT07493057 · 140 participants (planned) · Start Apr 22, 2026 · Primary completion Nov 14, 2027
Drug: Placebo; GZR18 injection · For: Obstructive Sleep Apnea (OSA)
Sites: Beijing, China
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07220772 · 4 participants (planned) · Start Feb 9, 2026 · Primary completion Jun 18, 2027
Drug: Mibavademab · For: Monogenic Obesity
Sites: Ulm, Germany; Esplugues de Llobregat, Spain; Ankara, Turkey (Türkiye) · 4 sites in all
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyPivotal-lookingRecruiting
Gan & Lee Pharmaceuticals.Industry
NCT07501832 · 140 participants (planned) · Start Apr 29, 2026 · Primary completion Sep 28, 2028
Drug: GZR18 injection; Placebo · For: Obstructive Sleep Apnea (OSA)
Sites: Beijing, China
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Pivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481747 · 2,539 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Sites: Shenzhen, China
- Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom OnsetPivotal-lookingRecruiting
Supergene, LLCIndustry
NCT07324837 · 1,050 participants (planned) · Start Jun 9, 2026 · Primary completion Nov 1, 2028
Drug: non-immunogenic staphylokinase; Placebo · For: Ischemic Stroke, Acute
Sites: Ryazan, Russia; Chelyabinsk, Russia; Irkutsk, Russia · 17 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.